Biotech | February 17, 2022
PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Two out of three people under the age of 40 are at risk of prediabetes
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
Subscribe To Our Newsletter & Stay Updated
